A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
← catalyst calendarNCT05617677 · readout in 61 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
516actual
Sites
197
Countries
Argentina, Brazil, Bulgaria +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-12 | actual | When the study began enrolling |
| Primary completion | 2026-10-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-13 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Interventions
- Drug: Deucravacitinib
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response
measured At week 52
Publications
- PMID 40920289 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed